Application of Desferal to Treat COVID-19

Phase 1

• Conditions: COVID-19
• Interventions: Drug: Deferoxamine

• Registration Number: NCT04333550
• Lead Sponsor: Kermanshah University of Medical Sciences

Brief Summary

In this study, defined cases of COVID-19 with mild, moderate or severe pneumonia will be treated with standard treatment regimens in combination with IV injection of Deferoxamine. Improvement in clinical, laboratory and radiological manifestations will be evaluated in treated patient compared to control group.

Detailed Description

Not available

Study Timeline

• Status Verified: 2020-04
• Study Start: 2020-04
• Study First Submitted: 2020-04-01
• Study First Submitted QC: 2020-04-01
• Study First Posted: 2020-04-03
• Last Update Submitted: 2020-04-30
• Last Update Posted: 2020-05-04
• Primary Completion: 2020-09
• Study Completion: 2021-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Clinical diagnosis of COVID-19 Disease,

Read More

Exclusion Criteria

Previous history of allergy to Deferoxamin, Pregnancy, kidney dysfunction,

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Experimental: standard treatment	Deferoxamine	-
Experimental: Desferal addition to standard treatment	Deferoxamine	-

Primary Outcome Measures

Name	Time	Method
Mortality rate	up to 20 days	All cause of death

Secondary Outcome Measures

Name	Time	Method
change in patients clinical manifestation	up to 20 days	Mild, Moderate or Severe
change in patients PaO2	up to 20 days
Length of hospitalization	up to 20 days	days
C-reactive protein	up to 20 days
lymphocyte count	up to 20 days
length of intensive care unit stay	1 to 20 days

Trial Locations

Locations (1)

Regenerative Medicine Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran; 🇮🇷 Kermanshah, Iran, Islamic Republic of